GlobeNewswire

Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum

Share
  • Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)[1]
     
  • Novartis plans FDA submission for nr-axSpA, having submitted to EMA previously[1]. This would be the fourth indication for Cosentyx[2],[3]
     
  • PREVENT underlines Cosentyx leadership and is a step forward in providing patients with a treatment that addresses the complete axSpA disease spectrum
     
  • There are approximately 1.7 million patients with nr-axSpA in the US and EU[4]             

Basel, October 02, 2019 Novartis, a leader in rheumatology and immuno-dermatology, today announced additional positive data from the PREVENT trial, evaluating the efficacy and safety of Cosentyx® (secukinumab) in patients with non-radiographic axial spondyloarthritis (nr-axSpA). The ongoing Phase III trial met its primary endpoint of ASAS40 at Week 52, showing a significant and clinically meaningful reduction in disease activity for patients treated with Cosentyx versus placebo. The trial demonstrated a sustained response and a safety profile consistent with previous clinical trials. No new safety signals were detected[1],[5-10].

Positive 16-week PREVENT data were announced mid-September and submitted to EMA for approval in nr-axSpA[11]. These data add to the five-years of clinical data supporting the long-term efficacy and safety of Cosentyx across ankylosing spondylitis, psoriatic arthritis and psoriasis[5-10].

“Non-radiographic axial spondyloarthritis is a chronic debilitating disease, which left untreated can have a significant impact on patients' quality of life,” said Atul Deodhar, MD, professor of medicine and medical director of Rheumatology Clinics at Oregon Health & Science University, and an investigator in the secukinumab clinical trial program. “These positive results indicate a potential new treatment option to help patients experience relief from the signs and symptoms of their disease.”

“These data are encouraging for people living with nr-axSpA, where there are only limited treatment options available,” said John Tsai, M.D., Head of Global Drug Development and Chief Medical Officer for Novartis. “It’s a great example of how we’re working to reimagine medicine to help patients realize early relief from this disease.”

Detailed data is planned to be presented at a future scientific congress.

About axSpA
Axial spondyloarthritis (axSpA) is a spectrum of long-term inflammatory disease characterized by chronic inflammatory back pain[12]. The axSpA disease spectrum includes ankylosing spondylitis (AS), in which joint damage is generally visible on x-ray, and non-radiographic axial spondyloarthritis (nr-axSpA), in which joint damage is not visible on x-ray[12],[13]. Both parts of the disease spectrum have a similar symptom burden, including nocturnal pain, fatigue, morning stiffness and functional disability[14]. If left untreated, axSpA could impair activity, lead to lost work time and have a significant impact on quality of life[14].

About PREVENT
PREVENT is an ongoing two-year randomized, double-blind, placebo-controlled Phase III study (with a two-year extension phase) to investigate the efficacy and safety of Cosentyx, in patients with active nr-axSpA. The study enrolled 555 male and female adult patients with active nr-axSpA (with onset before 45 years of age, spinal pain rated as ≥40/100 on a visual analog scale (VAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥4) and who had been taking at least two different non-steroidal anti-inflammatory drugs (NSAIDs) at the highest dose up to 4 weeks prior to study start. Patients may have previously taken an TNF inhibitor (not more than one) but had had an inadequate response. Of the 555 patients enrolled in the study, 501 (90%) were biologic naive. Patients were allocated to one of three treatment groups: Cosentyx 150 mg subcutaneously with loading dose (Induction: 150 mg Secukinumab subcutaneously weekly for 4 weeks, then maintenance with 150 mg Secukinumab monthly); Cosentyx 150 mg no loading dose (150 mg Secukinumab subcutaneously monthly), or placebo (induction of subcutaneously weekly for 4 weeks, followed by maintenance of once-monthly)[1].

The primary endpoints are the proportion of patients achieving an ASAS40 response with Cosentyx 150 mg at weeks 16 and 52. Secondary endpoints include change in BASDAI over time and change in the Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP)[1].

ASAS40 is achieved when there is a measure of an improvement of at least 40% and an improvement of at least 10 units on a 0–100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function (Bath Ankylosing Spondylitis Functional Index (BASFI)), and Inflammation (morning stiffness severity and duration) and no worsening in the remaining domains[15]. BASDAI assesses a patient’s disease activity on six measures: fatigue, spinal pain, joint pain/swelling, enthesitis, morning stiffness duration and morning stiffness severity[15].

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “plans,” “submitted,” “would,” “step forward,” “ongoing,” “supporting,” “potential,” “encouraging,” “planned,” “could,” “to investigate,” “expectations,” or similar terms, or by express or implied discussions regarding potential new indications or labeling for Cosentyx, or regarding potential future revenues from Cosentyx. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Cosentyx will be submitted or approved for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Cosentyx will be commercially successful in the future. In particular, our expectations regarding Cosentyx could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis or follow @NovartisNews for the latest News & Media Updates at https://twitter.com/novartisnews
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

References

[1]     Novartis data on file. September 2019.
[2]    Cosentyx [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2018. 
[3]     Novartis Europharm Limited. Cosentyx (secukinumab): Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf. Last accessed: September 2019.
[4]     DRG Epidemiology Database - Axial Spondyloarthritis: Disease Landscape & Forecast. August 2019. Available from: https://decisionresourcesgroup.com/report/716950-biopharma-axial-spondyloarthritis-landscape-forecast/. Last accessed: September 2019.
[5]     Data on file. CAIN457F2310 (MEASURE 2): 5 Year Report. Novartis Pharmaceuticals Corp; September 15, 2015.
[6]     Data on file. Data Analysis Report: Study CAIN457A2302E1. Novartis Pharmaceuticals Corp; November 30, 2015.
[7]     Data on file. CAIN457F2310 and CAIN457F2305 Summary of 5-Year Clinical Safety in (Ankylosing Spondylitis). Novartis Pharmaceuticals Corp; May 2019.
[8]     Data on file. CAIN457F2312 (FUTURE 2): 5 Year- Interim Report. Novartis Pharmaceuticals Corp; May 2019.
[9]     Data on file. CAIN457F2312 Data Analysis Report. Novartis Pharmaceuticals Corp; November 2008.
[10]   Data on file. CAIN457F2310 (MEASURE 1 and 2): Pooled Safety Data. Novartis Pharmaceuticals Corp; July 23, 2018.
[11]   Novartis press release. Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis. Available from: https://www.novartis.com/news/media-releases/novartis-cosentyx-positive-16-week-prevent-results-advance-potential-new-indication-patients-axial-spondyloarthritis. Last accessed: September 2019.
[12]   Strand V, et al. Patient Burden of Axial Spondyloarthritis. J Clin Rheumatol. 2017 Oct;23(7):383–391.
[13]   Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777-783.
[14]   Mease PJ, van der Heijde D, Karki C, et al. Characterization of patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis in the US-based Corrona Registry. Arthritis Care Res (Hoboken). 2018;70(11):1661-1670.
[15]   Landewe R, et al. Clinical Tools to Assess and Monitor Spondyloarthritis. Curr Rheumatol Rep. 2015;17(7):47.

# # #

Novartis Global External Communications
E-mail: media.relations@novartis.com

Antonio Ligi
Novartis Global External Communications
+41 61 324 1374 (direct)
antonio.ligi@novartis.com

 

Eric Althoff
Novartis US External Communications
+1 646 438 4335
eric.althoff@novartis.com
Friedrich von Heyl
Novartis Pharma Communications
+41 61 324 8984 (direct)
+41 79 749 0286 (mobile)
friedrich.vonheyl@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central   North America  
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052
Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 778 3258
Thomas Hungerbuehler +41 61 324 8425    
Isabella Zinck +41 61 324 7188    

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Golar LNG Partners LP: Q3 2019 results presentation21.10.2019 14:19:00 CESTPress release

Golar LNG Partners LP 3rd Quarter 2019 results will be released before the NASDAQ opens on Tuesday November 26, 2019. In connection with this a webcast presentation will be held at 4:30 P.M (London Time) on Tuesday, November 26, 2019. The presentation will be available to download from the Investor Relations section at www.golarlngpartners.com This webcast will be immediately followed by a Q&A session. Participants will be able to join this webcast by dialling-in using the following details: a. Webcast Go to the Investors, Results Centre section at www.golarlngpartners.com and click on the link to "Webcast". To listen to the conference call from the web, you need to have installed Windows Media Player, and you need to have a sound card on your computer. b. Teleconference Call-in numbers: International call +44 2071 928 000 UK Free call 0800 376 7922 US Toll +1 631 510 7495 USA Free call 866 966 1396 Norway Toll +47 23 96 02 64 Norway Free call 800 51874 The participants will be asked f

Rovio Entertainment Corp.: Capital Markets Day 2019 Agenda21.10.2019 14:16:00 CESTPress release

Rovio Entertainment Corporation Press Release Oct. 21, 2019 Rovio Entertainment is organizing Capital Markets Day for analysts, institutional investors and financial media on Monday November 4th, 2019. Location: Kluuvikatu 4, 00100 Helsinki, Finland During the day Rovio’s CEO Kati Levoranta, together with members of Games leadership and other senior management, will present an overview on Rovio’s strategy, including a deep dive into the games portfolio and growth strategy. A short Q&A session is scheduled after each presentation and at the end of the day. Capital Markets Day 2019 agenda (all times in EET): 12:00-13:00 Registration & lunch 13:00-13:40 Rovio overview & strategy: winning in a dynamic growth market 13:40-13:55 Passionate, skillful teams and inspiring culture 13:55-15:10 Games - our unique approach to drive growth 15:10-15:25 Coffee Break 15:25-15:45 Angry Birds - building long-term franchise growth 15:45-16:00 Hatch - pioneering mobile game streaming 16:00-16:30 Financials

Norsk Hydro: REMINDER: Invitation - Hydro’s third quarter results 201921.10.2019 14:04:00 CESTPress release

Hydro's third quarter results 2019 will be released at 07:00 CEST (01:00 AM EDT, 06:00 UK time), on Wednesday October 23, 2019. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Presentation in Oslo Hydro will host a combined analyst and press conference, in English, at its corporate headquarters at Drammensveien 260, Oslo, at 08:30 CEST the same day. The presentation will be held by President and CEO Hilde Merete Aasheim and CFO Pål Kildemo and can also be seen on webcast. To attend the presentation in Oslo, please register by sending a mail to ir@hydro.com. In addition to the webcast, where it will be possible to ask questions in writing, it will also be possible to dial in (not possible to ask questions over the phone). To join this event, please use the below “Click to Join” link 5-10 minutes prior to start time (choose “Click to Join” twice), where you will be asked to enter your phone number and registration details. The Event Confe

Norsk Hydro: PÅMINNELSE: Invitasjon - Presentasjon av Hydros resultat for tredje kvartal 201921.10.2019 14:04:00 CESTPressemelding

Hydros resultat for tredje kvartal 2019 blir offentliggjort onsdag 23. oktober 2019 kl. 07.00. Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Presentasjon i Oslo Det blir holdt en kombinert analytikerpresentasjon og pressekonferanse ved Hydros hovedkontor i Drammensveien 260, Oslo, samme dag, kl. 08.30. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for Økonomi og finans Pål Kildemo. Hele presentasjonen kan sees direkte på web-TV. For påmelding, vennligst send mail til ir@hydro.com. I tillegg til web-TV, hvor det vil være mulig å stille spørsmål skriftlig, vil det også være mulig å ringe inn (ikke mulig å stille spørsmål over telefon). Du melder deg på denne telefonkonferansen ved å klikke på lenken “Click to Join“ 5-10 minutter før start (velg “Click to Join“ to ganger), hvor du må oppgi telefonnummer og registreringsdetaljer. Konferansesystemet vil ringe tilbake på det oppgitte telefonnummeret og plas

Valmet to supply a coated board machine to Graphic Packaging International in the United States21.10.2019 14:00:00 CESTPress release

Valmet Oyj’s press release on October 21, 2019 at 3:00 p.m. EET Valmet will supply a coated board machine for Graphic Packaging International’s (GPI) mill in Kalamazoo, Michigan, in the United States. With this investment in the latest coated board technology, GPI is committing to sustainable packaging with exceptional product quality and cost competitiveness for producing coated recycled board (CRB) grades. The start-up of the machine is scheduled for the first half of 2022. The order is included in Valmet's orders received of the third quarter 2019. The value of the order is not disclosed. “Valmet has offered us innovative yet proven technology to reach our high product quality targets. We have had a long and good cooperation with Valmet. Our relationship is based on mutual trust, which is very important in large projects like this one,” says Rusty Miller, Senior Vice President, Engineering and Technology, GPI. “Valmet has a very good relationship with Graphic Packaging International

Klövern säljer 42 fastigheter i Karlstad för 2 610 mkr21.10.2019 13:10:00 CESTPressemelding

Klövern har tecknat avtal om att avyttra hela sitt fastighetsbestånd i Karlstad, bestående av 42 fastigheter, för ett sammanlagt underliggande fastighetsvärde om 2 610 mkr. Fastigheternas uthyrningsbara yta uppgår till cirka 204 000 kvm och utgörs huvudsakligen av kontor samt lager/logistik. Hyresvärdet uppgår till 247 mkr och den ekonomiska uthyrningsgraden uppgår till 95 procent. Transaktionen görs i syfte att geografiskt renodla Klöverns fastighetsportfölj till färre orter. Frånträde är planerat till den 29 november 2019. Transaktionen omfattar följande fastigheter: Barkassen 7 Bälgen 11 Kanoten 10 Stolpen 1 Barkassen 9 Druvan 13 Kulingen 4 Stolpen 6 Björnen 13 Ekorren 11 Mercurius 3 Styrmannen 5 Björnen 7 Fjädern 14 Monitorn 9 Sågen 1 Blåsten 3 Fjädern 16 Passadvinden 3 Sågen 2 Blåsten 4 Freja 13 Pinassen 2 Sågen 9 Brisen 4 Grästegen 2 Regnvinden 1 Tornadon 2 Bromsen 1 Gångjärnet 2 Skepparen 15 Tången 15 Bromsen 6 Hammaren 21 Släggan 13 Ugnen 1 Bälgen 9 Herrhagen 1:10 Spärren 7 Vän